.svg)
As featured in Drug Discovery & Development, 2026
Drug Discovery Trends recently featured how ConcertAI has transformed CancerLinQ® into a point-of-care oncology intelligence platform, highlighting its evolution from a quality reporting tool into an AI-powered solution that delivers actionable insights within oncology workflows.
The article includes perspectives from Eron Kelly, CEO of ConcertAI, and Shaalan Beg, MD, Chief Medical Officer, Oncology, who discuss how CancerLinQ is helping bridge the gap between clinical care and research through AI, real-world data, clinical decision support, and trial matching. They also share how workflow-integrated intelligence is helping oncology teams identify care gaps, expand access to clinical trials, and support more informed treatment decisions.